Table 5.
Risk of cancer and cancer-related death with ARBs
| Comparator |
Cancer odds ratios, 95% CI |
Cancer-related death odds ratios, 95% CI |
||||
|---|---|---|---|---|---|---|
| Direct comparison (Peto OR) | Multiple comparisons (fixed effect) | Multiple comparisons (random effects) | Direct comparison (Peto OR) | Multiple comparisons (fixed effect) | Multiple comparisons (random effects) | |
| ACEis | 0.96 (0.86–1.06) | 0.99 (0.92–1.07) | 0.99 (0.84–1.09) | 0.97 (0.83–1.14) | 0.95 (0.83–1.07) | 0.93 (0.80–1.08) |
| β Blockers | 0.89 (0.76–1.04) | 0.96 (0.88–1.05) | 0.96 (0.82–1.08) | 0.97 (0.74–1.26) | 0.93 (0.80–1.08) | 0.97 (0.80–1.19) |
| CCBs | 1.18 (1.04–1.33) | 1.04 (0.96–1.11) | 1.03 (0.92–1.16) | 1.19 (0.40–3.56) | 0.96 (0.82–1.10) | 0.96 (0.78–1.16) |
| Diuretics | 1.01 (0.06–16.67) | 0.99 (0.90–1.09) | 0.98 (0.82–1.25) | – | 0.98 (0.84–1.13) | 0.97 (0.78–1.17) |
| Controls | 1.05 (0.76–1.47) | 0.96 (0.74–1.22) | 0.96 (0.70–1.37) | 1.30 (0.75–2.27) | 1.08 (0.79–1.44) | 1.08 (0.81–1.40) |
| ACEis + ARBs | 1.10 (0.99–1.22) | 1.13 (1.03–1.24) | 1.14 (0.93–1.33) | 1.07 (0.90–1.27) | 1.09 (0.94–1.27) | 1.06 (0.87–1.30) |
Reprinted from The Lancet Oncology, volume 12, issue 1, Bangalore et al, ‘Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials’, pp 65–82, Copyright 2011, with permission from Elsevier.56
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium-channel blocker; CI, confidence interval; OR, odds ratio.